Mineralys Therapeutics, Inc. MLYS Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Mineralys Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Mineralys Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mineralys Therapeutics, Inc.'s interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mineralys Therapeutics, Inc.'s interest income (expense), nonoperating?
- Mineralys Therapeutics, Inc. (MLYS) reported interest income (expense), nonoperating of $6M in Q1 2026.
- How has Mineralys Therapeutics, Inc.'s interest income (expense), nonoperating changed year-over-year?
- Mineralys Therapeutics, Inc.'s interest income (expense), nonoperating increased by 167.8% year-over-year, from $2.24M to $6M.
- What is the long-term trend for Mineralys Therapeutics, Inc.'s interest income (expense), nonoperating?
- Over 3 years (2022 to 2025), Mineralys Therapeutics, Inc.'s interest income (expense), nonoperating has grown at a 111.9% compound annual growth rate (CAGR), from $1.68M to $15.95M.